P53 links tumor development to cancer therapy

25 Years of p53 Research

Volumn , Issue , 2005, Pages 339-351

  Hemann, Michael T ^a   Lowe, Scott W ^a  

^a Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646800191     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-2922-6_15     Document Type: Chapter

References (57)

1. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538.
2. Ahn, J., Urist, M., and Prives, C. (2003). Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 278, 20480-20489.
3. Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., Shiloh, Y., Crawley, J. N., Ried, T., Tagle, D., and Wynshaw-Boris, A. (1996). Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171.
4. Bullock, A. N., and Fersht, A. R. (2001). Rescuing the function of mutant p53. Nat Rev Cancer 1, 68-76.
5. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104, 263-269.
6. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852.
7. de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W. (1998). E1A signaling to p53 involves the p19 (ARF) tumor suppressor. Genes Dev 12, 2434-2442.
8. Debbas, M., and White, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7, 546-554.
9. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
10. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., and Cleveland, J. L. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13, 2658-2669.
11. Ferreira, C. G., Tolis, C., and Giaccone, G. (1999). p53 and chemosensitivity. Ann Oncol 10, 1011-1021.
12. Fridman, J. S., Hernando, E., Hemann, M. T., de Stanchina, E., Cordon-Cardo, C., and Lowe, S. W. (2003). Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 63, 5703-5706.
13. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 4855-4878.
14. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3, 639-645.
15. Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., and Lowe, S. W. (2003). An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33, 396-400.
16. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW (2004). Suppression of tumorigenesis by the p53 target PUMA. PNAS 101, 9333-9338.
17. Hermeking, H., and Eick, D. (1994). Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093.
18. Herr, I., and Debatin, K. M. (2001). Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603-2614.
19. Horowitz, J. (1999). Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1, 500-509.
20. Hussain, S. P., and Harris, C. C. (1998). Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58, 4023-4037.
21. Iliakis, G., Wang, Y., Guan, J., and Wang, H. (2003). DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22, 5834-5847.
22. Jallepalli, P. V., Lengauer, C., Vogelstein, B., and Bunz, F. (2003). The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 278, 20475-20479.
23. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
24. Johnstone, R. W., Ruefli, A. A., and Smyth, M. J. (2000). Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25, 1-6.
25. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659.
26. Kemp, C. J., Donehower, L. A., Bradley, A., and Balmain, A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822.
27. Komarova, E. A., Christov, K., Faerman, A. I., and Gudkov, A. V. (2000). Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 19, 3791-3798.
28. Liao, M. J., Yin, C., Barlow, C., Wynshaw-Boris, A., and van Dyke, T. (1999). Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol Cell Biol 19, 3095-3102.
29. Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., and Lozano, G. (2004). Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36, 63-68.
30. Lowe, S. W., and Ruley, H. E. (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7, 535-545.
31. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
32. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
33. Lozano, G., and Liu, G. (1998). Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 8, 337-344.
34. Lu, X., Magrane, G., Yin, C., Louis, D. N., Gray, J., and Van Dyke, T. (2001). Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol 21, 6017-6030.
35. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., and et al. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708.
36. Prives, C. (1998). Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5-8.
37. Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., and White, E. (1992). The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A 89, 7742-7746.
38. Rogoff, H. A., Pickering, M. T., Debatis, M. E., Jones, S., and Kowalik, T. F. (2002). E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol 22, 5308-5318.
39. Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., and Lowe, S. W. (2002a). Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298.
40. Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., and Lowe, S. W. (2002b). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
41. Schmitt, C. A., and Lowe, S. W. (1999). Apoptosis and therapy. J Pathol 187, 127-137.
42. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., and Lowe, S. W. (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13, 2670-2677.
43. Schwartz, D., and Rotter, V. (1998). p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 8, 325-336.
44. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
45. Soussi, T., and Beroud, C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1, 233-240.
46. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. (1998). The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 17, 5001-5014.
47. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. (1994). p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711.
48. Tolbert, D., Lu, X., Yin, C., Tantama, M., and Van Dyke, T. (2002). p19 (ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol 22, 370-377.
49. Tsai, K. Y., MacPherson, D., Rubinson, D. A., Crowley, D., and Jacks, T. (2002). ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol 12, 159-163.
50. Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., and Wahl, G. M. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9, 1031-1044.
51. Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307-310.
52. Volm, M. (1998). Multidrug resistance and its reversal. Anticancer Res 18, 2905-2917.
53. Vousden, K. H., and Lu, X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604.
54. Wallace-Brodeur, R. R., and Lowe, S. W. (1999). Clinical implications of p53 mutations. Cell Mol Life Sci 55, 64-75.
55. Xu, Y., Yang, E. M., Brugarolas, J., Jacks, T., and Baltimore, D. (1998). Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/-mice. Mol Cell Biol 18, 4385-4390.
56. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
57. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12, 2424-2433.